Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There are reasons beyond what is published as to the reason why VRNG is delaying the filing for en banc. Clearly this CAFC obviousness decision is going to make a lot of patent holders upset (possible including GOOG itself). Is it possible that the delay was to give time from VRNG to rally the support and influence of the Apples, IBMs, Microsofts, etc., in order to try and increase the chances of an en banc review?? I am hoping this is the case.
See my post on the IV message board:
http://www.investorvillage.com/smbd.asp?mb=2013&mn=6902&pt=msg&mid=14077466
Your message as it appears in the headline summary "Just don't let her cut your sausage" instantly reminded me of Lorena Bobbitt!! LOL.
No injunction possible for NPEs. Have been through this many many times.
This is not new information. This exact news came out on February 24th.
The chances of winning is much higher for Google on the first two appeals. This might have weighted heavily in their decision not to consolidate.
Not only through appeals - also through SCOTUS!!
Don't forget taxes and lawyers' contingency fees.
What I would like to see is a history of VHC short positions matched up with the share price during its period of rice and see if there is any correlation.
From the little I know about VHC, its future total winnings under the current lawsuits is expected to be less than that of VRNG (correct me if I am wrong). Very roughly, VRNG has approx 2X the amount of shares outstanding, potentially. So on the peripheral analysis, one would expect that VRNG's share price should be at least 50% of VHC - which means a double from here. It may eventually get there after the shorts have escaped.
RedA: Today is a perfect illustration of the quote you pasted. Did you see that ridiculous Street.com article?
Worth re-reading this at this time:
http://counterfeitingstock.com/CounterfeitingStock.html
Street.com publishes their usual negative article to help the shorts out. This is probably what caused the dip back to the 5.20s.
Street.com publishes their usual negative article to help the shorts out. This is probably what caused the dip back to the 5.20s.
Just "having data" is not going to cut it with FDA, because this data was not gathered in a formal FDA-approved IND. If RCP is lucky, FDA may give approval for a Phase1/II combined trial. But getting the "use" patent is the first key step. Then comes financing. It is possible that JH or another research institution might provide this - I hope so. Eventually I see no option but get bought. I hope this comes about at a much higher stock price.
<<next quarter should see a surge in popularity and sales>>
I have heard this phrase now for 2 years from some in this Board. Ain't gonna happen. It is going to take a lot more than the publication to grow revenues.
I honestly want to see STSI and anatabine products succeed. However, we should not be blinded by "wanting" and "hoping". The key question now is where is the money coming from to move forward. Unless this is answered satisfactorily, we are not going to see much of an upward price movement. Shorts are going to continue to own the stock price.
Agreed. The reality is that the pps will stay or move lower until there is some resolution to the financial security of the company in terms of cash. STSI needs a major JV with a pharma to get the trials going and this is going to demand a significant dilution. Even this will only take it up to Phase 1. Then more dilution for Phase 2 trials. Eventually STSI will have ne option but to be bought out cheaply by tha JV pharma or someone else.
I had hoped that NJ's uber-optimism on A-block sales would at least by 25% justified but this is not so. Being an A-block user, I just hope that it will coninue to be available for all the users out there even if STSI gets bought out.
Red Angus: you have echoed my thoughts and expressed it far more eloquently than I could ever. Simply put, HJJ just does not want the responsibility of ruling a large payment against GOOG even though the Jury and other evidences would dictate one.
The management change is very good news indeed. PP was getting well past it and JW had too much negative image surrounding him. Mullen is reputed to be a great scientist, but how ell will he do as a CEO? Only time will tell. Hopefully he will have enough experts around him to help him make decisions on areas where he has little experience.
The main question is cash. Where is STSI going to get all this money from for the very expensive clinical trials? It has to be through collaboration with a pharma. That pharma will want a large piece of the pie and that is probably the reason for the proposed increase in the number of shares. I fear that this may be just be the first step in the dilution process. Unfortunately the low stock price means greater dilution,
What is needed now are comments from some medical experts who are neither pumpers or bashers of the stock. From my very lay eyes, the results look interesting but not spectacular (not enough by itself to impact stock price). Clearly, more studies are needed which is going to cost more $$$. There were many expectations here that a peer-reviewed study will provide a catalyst for stock price appreciation. I don't think this is going to happen.
STSI needs cash and it needs approval of the "use" patent to move forward.
Where is the CRP study results, and whatever happened to the Pisa study? Star has been very quiet for almost a year on all of these.
No. This 295 patent is the manufacturing or synthesizing patent. Nice to have but not nearly as important as the "use" patent, which, if and when granted, will provide STSI exclusive rights for the use of certain isonomers of anatabine citrate on specific medical conditions. If peer-reviewed studies prove that these isonomers are highly effective against the said conditions, the granting of the "use" patent will provide the impetus to the stock price that the longs are looking for. Main problem is we don't know if and when STSI will get this and how STSI will survive cash-wise before it does.
Completely agree after having invested in some patent infringement cases. STSI's tobacco manufacturing patents are also a case in point. What did STSI get in the end after a decade of litigation. The risk of a work-around for manufacturing patents is always high.
For more beneficial for STSI would be approval for the "use" patent. This is when I believe that pharma interest will really start to open up.
I don't think Google is too worried whether the ultimate amount happens to to $1B or $0.5B. Their strategy is to cause maximum pain and delay to VRNG as a warning to other potential patent holders seeking to claim their bite out of GOOG. GOOG is not going to settle.
Willow: don't start making connections without checking some facts. I AM NOT Nomo. I have not posted previously on iHub but, in the past, on investor village and Yahoo clown board - and bullishly so. Just because I have become more negative on STSI does not mean I am here with an agenda. The board is only useful if honest opinions are given rather than just cheer-leading optimism.
I agree with you. I believed (and still do) in A-block as a great product and the benefits of anatabine. I invested a large amount in STSI but have sold practically all of it at a great loss because I have deep concerns about the stock.
Firstly the cash flow situation looks quite awful. In order to survive, it will have to raise money and dilute sooner or later. The other alternative is to be bought for a pittance relative to its potential worth. A-block is just not selling well enough to overcome these cash problems.
Secondly, management is awful. It did a terrible job on the tobacco side, inspite of winning. Remember the fiasco concerning the mistakes in the initial press release of the results of one of the studies last year? This is one of the most investor-unfriendly stocks in the marketplace. It doesn't hold any conference calls for the public, but only for a select few investors. The marketplace, probably quite rightly, does not trust JW.
Thirdly, I really do think that STSI is on to something regarding anatabine and its role in controlling NFkB. In fact, so much that big-pharma is likely to do anything in its immense power to kill it.
I will continue to keep a close watch on this stock, if the three things mentioned above improve, I will become more interested as an owner.